Novartis AG (NVS)
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| April 25, 2025 | $3.99 | 2025-03-12 | 2025-03-12 |
| April 19, 2024 | $3.74 | 2024-03-07 | 2024-03-08 |
| March 20, 2023 | $3.50 | 2023-03-09 | 2023-03-10 |
| March 17, 2022 | $3.33 | 2022-03-08 | 2022-03-09 |
| March 15, 2021 | $3.20 | 2021-03-04 | 2021-03-05 |
Dividends Summary
- Novartis AG has issued 22 dividend payments over the past 21 years
- The most recent dividend was paid 148 days ago, on April 25, 2025
- The highest dividend payed out to investors during this period was $3.99399 per share
- The average dividend paid during this period was $2.44 per share.
Company News
A comprehensive report on South Africa's pharmaceutical industry highlights market growth, challenges, and opportunities, focusing on local manufacturing, healthcare innovation, and emerging market trends.
Law firm Monteverde & Associates is investigating the proposed sale of Tourmaline Bio to Novartis, where shareholders will receive $48.00 per share, to determine if the transaction is fair.
Novartis is pioneering radioligand therapy, a targeted cancer treatment that shows promising clinical results. The company estimates the market could reach $25-30 billion, but the technology is still nascent and will take 10-15 years to become mainstream.
Two pharmaceutical companies, Johnson & Johnson and Novartis, are facing patent cliff challenges but demonstrate resilience through diversified product portfolios, innovative pipelines, and consistent dividend growth.
Incyte Corporation is expected to report strong Q2 2024 earnings, driven by increased sales of its lead drug Jakafi and other newly approved drugs. The company's earnings are likely to benefit from higher royalties from Novartis for the commercialization of Jakafi in ex-U.S. markets.